Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2021-04-01 Annual Report
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
Annual information form - English.pdf
Annual Report Classification · 95% confidence The document is titled 'Annual Information Form' for the eight month period ended December 31, 2020, dated March 30, 2021. It contains detailed sections such as Corporate Structure, Description of Business, Drug Development Process, Clinical Trials, Regulatory Affairs, Financing, Risk Factors, Dividends, Capital Structure, Directors and Executive Officers, Audit Committee Matters, and other comprehensive corporate and financial information. The length is substantial (15,000 characters) and it includes detailed business and financial disclosures typical of an annual report. The document is not a brief announcement or a certification letter, nor is it a transcript, presentation, or voting result. It is a comprehensive annual disclosure document, which aligns with the definition of an Annual Report (10-K). Although titled 'Annual Information Form', this is a recognized type of annual disclosure document similar in purpose to a 10-K filing, providing a full overview of company activities and financial performance for the fiscal year. Therefore, the appropriate classification is Annual Report (10-K).
2021-04-01 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the publication of scientific research findings related to the drug apabetalone and its effects on COVID-19. It highlights the publication in the journal Cell and discusses the research and upcoming clinical trials. There is no indication that this document contains financial statements, regulatory filings, management discussions, or any formal corporate report. It is an informational announcement about scientific research and program updates, not a financial or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is more aligned with a general corporate announcement or news release. Since none of the specific categories for financial or regulatory filings apply, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other categories.
2021-03-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a scientific article about apabetalone's potential to prevent COVID-19 infection. It discusses research findings, collaboration details, and future clinical trial plans. There are no financial statements, regulatory filings, or corporate governance information. The document is not a financial report, earnings release, or management discussion. It is a program update and scientific publication announcement related to the company's drug development. This type of document fits best under Regulatory Filings (RNS) as a general regulatory announcement and scientific update that does not fit other specific categories.
2021-03-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a change in the company's fiscal year-end from April 30 to December 31. It discusses the implications of this change for future financial reporting periods and mentions the filing of the required notice under National Instrument 51-102 on SEDAR. The document does not contain any actual financial statements, detailed financial data, or comprehensive financial analysis. It is an announcement about a change in reporting periods rather than a report itself. The document length is 4283 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit into other specific categories.
2021-03-12 English
Notice.pdf
Regulatory Filings
2021-03-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing new published scientific evidence regarding the drug apabetalone's potential benefits against COVID-19. It references a recently published article on a pre-print server and discusses ongoing research and clinical plans. There are no financial statements, regulatory filings, or corporate governance details. The content is primarily a news announcement about research findings and future clinical trials, not a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate news announcement about research progress and publication, which aligns best with Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2021-03-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.